Head-to-head evidence
tezepelumab vs Tezepelumab (APFS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
tezepelumab · Tezspire
Marketed by AstraZeneca and partners
NCT03347279 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.
Next expected readout: November 2026 · NCT06705764 (registry estimate)
Tezepelumab (APFS)
Marketed by AstraZeneca
NCT03968978 · Phase 3 · completed
The study randomized 216 participants 1:1 to two active device types but was open-label, with no placebo or blinded control. Its primary endpoint was successful device administration rather than a clinical asthma outcome, and although arm-specific results were posted, the registry does not state whether the between-device comparison was statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tezepelumab's landscape · Tezepelumab (APFS)'s landscape